Columnist Samuel Kirton talks with the Pulmonary Fibrosis Foundation's Amy Hajari Case, MD, about the Accelerate Research ...

Winning its second FDA approval this year, Boehringer Ingelheim's oral drug Jascayd is now cleared for use in the U.S. by ...

GRI-0621, an experimental oral therapy from GRI Bio, boosts lung function in adults with IPF, according to top-line clinical ...

Columnist Sam Kirton has wonderful memories of holiday presents, but the greatest gift he's received came in the form of a lung transplant.

Caring for someone you love is intimate, humbling, and grounding, writes columnist Ann Reynoso, who swapped caregiver roles with her husband.

[vc_row][vc_column][vc_column_text]Pulmonary fibrosis (PF) is a respiratory disease that causes the lung tissue to become thick and stiff. Over time, it turns into scar tissue, which is known as ...

Building on positive Phase 2 data, Puretech plans to launch a Phase 3 trial to further evaluate its experimental IPF therapy ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Birchbiomed’s FS2 (kynurenic acid) for the treatment of idiopathic pulmonary fibrosis (IPF). Orphan drug status is ...

Bionews, Inc., the parent company of this site, has partnered with the following nonprofit advocacy organizations to help further the mission of ensuring that patients and caregivers are able to get ...